S&P Futures
3,923.25 +19.50 (+0.50%) Dow Futures
31,592.00 +171.00 (+0.54%) Nasdaq Futures
12,092.00 +51.50 (+0.43%) Russell 2000 Futures
1,782.40 +12.60 (+0.71%) Crude Oil
111.55 +1.98 (+1.81%) Gold
1,826.30 +1.50 (+0.08%)
Cumberland Pharmaceuticals Inc. (CPIX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 2.1000 |
| Open | 2.1400 |
| Bid | 0.0000 x 2200 |
| Ask | 0.0000 x 800 |
| Day's Range | 2.0600 - 2.1400 |
| 52 Week Range | 1.8900 - 7.5100 |
| Volume | |
| Avg. Volume | 31,203 |
| Market Cap | 30.419M |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3410 |
| Earnings Date | Aug 08, 2022 - Aug 12, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for CPIX
Related Research
- Cumberland Pharmaceuticals Inc.PCRX: Raising target price to $59.00PACIRA BIOSCIENCES INC has an Investment Rating of BUY; a target price of $59.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.RatingFair ValueEconomic Moat6 days agoArgus Research
- Simply Wall St.
Estimating The Intrinsic Value Of Cumberland Pharmaceuticals Inc. (NASDAQ:CPIX)
Does the May share price for Cumberland Pharmaceuticals Inc. ( NASDAQ:CPIX ) reflect what it's really worth? Today, we...
- PR Newswire
Cumberland Pharmaceuticals Reports 6% Revenue Growth
Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company today announced that the Company's product portfolio of FDA-approved brands delivered combined revenues of $11.2 million during the first quarter of 2022, - which is a 6% increase over the prior year period. Adjusted earnings for the quarter were $0.5 million, or $0.03 a share. The company ended the first quarter with $96.7 million in total assets, $55.9 million in total liabilities, and $41.0 million of sharehold
- PR Newswire
Cumberland Pharmaceuticals Announces Key Co-Promotion Agreement with Verity Pharmaceuticals to Expand Support for Sancuso®
Specialty pharmaceutical company Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) announced today that it has entered into a national co-promotion agreement with Verity Pharmaceuticals International Ltd. to support Cumberland's new Sancuso® oncology support product.
